M&A Deal Summary

Charles River Laboratories International Acquires Chantest

On October 29, 2014, Charles River Laboratories International acquired life science company Chantest from Ampersand Capital Partners and Symmetric Capital

Acquisition Highlights
  • This is Charles River Laboratories International’s 12th transaction in the Life Science sector.
  • This is Charles River Laboratories International’s 7th transaction in the United States.
  • This is Charles River Laboratories International’s 1st transaction in Ohio.

M&A Deal Summary

Date 2014-10-29
Target Chantest
Sector Life Science
Buyer(s) Charles River Laboratories International
Sellers(s) Ampersand Capital Partners
Symmetric Capital
Deal Type Add-on Acquisition

Target

Chantest

Cleveland, Ohio, United States
ChanTest, is a provider of specialized laboratory testing services for drug development. ChanTest specializes in measuring interactions between drug candidates and proteins known as ion channels.

Search 201,771 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Charles River Laboratories International

Wilmington, Massachusetts, United States

Category Company
Founded 1947
Sector Life Science
Employees20,400
Revenue 4.1B USD (2023)
DESCRIPTION

Charles River Laboratories International is a provider of essential products and contract services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Charles River Laboratories International was incorporated in 1947 and is based in Wilmington, Massachusetts.


DEAL STATS #
Overall 13 of 31
Sector (Life Science) 12 of 28
Type (Add-on Acquisition) 8 of 26
State (Ohio) 1 of 2
Country (United States) 7 of 20
Year (2014) 5 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-07-09 Vivopath

Worcester, Massachusetts, United States

Vivopath, LLC is a discovery service provider with established experience and expertise in providing in vivo pharmacology studies, with specific focus in the areas of metabolic and inflammatory diseases.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-05-06 Sunrise Farms

Catskill, New York, United States

Sunrise Farms, Inc. offers poultry processing services and distributes poultry products.

Buy -

Seller(S) 2

SELLER

Ampersand Capital Partners

Wellesley, Massachusetts, United States

Investor Investor Investor Investor Investor


Category Growth Capital Firm
Founded 1988
PE ASSETS 3.0B USD
Size Large
Type Sector Focused
DESCRIPTION

Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $100 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.


DEAL STATS #
Overall 22 of 55
Sector (Life Science) 9 of 25
Type (Add-on Acquisition) 16 of 38
State (Ohio) 1 of 1
Country (United States) 22 of 51
Year (2014) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-07-01 Viracor-IBT Laboratories

Lee's Summit, Missouri, United States

Viracor-IBT Laboratories, Inc. provides infectious disease testing, immune monitoring, and bioanalytical services to vaccine, pharmaceutical, biotech, and medical device developers.

Sell $255M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-01-06 Azurity Pharmaceuticals

Woburn, Massachusetts, United States

Azurity Pharmaceuticals is a privately held, specialty pharmaceutical company focusing on the development and commercialization of value-added proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry. Azurity Pharmaceuticals was founded in 1998 and is based in Woburn, Massachusetts.

Buy -
SELLER

Symmetric Capital

Burlington, Massachusetts, United States

Investor Investor Investor


Category Private Equity Firm
Founded 2007
PE ASSETS 202M USD
Size Small
Type Sector Agnostic
DESCRIPTION

Symmetric Capital is a private equity firm that invests in profitable growth companies in the US and Canada. Symmetric seeks to invest $5 to $25 million to help fund shareholder liquidity needs, growth, acquisitions, or debt reduction. Symmetric will consider majority or minority positions and typically looks for market-leading companies owned by their founders, a family, or small partnership. Sectors of interest include business services, healthcare and life sciences, software, IT services, applied technology, industrial products, education, logistics and distribution, and consumer products. Symmetric was formed in 2007 and is based in Waltham, Massachusetts.


DEAL STATS #
Overall 10 of 14
Sector (Life Science) 1 of 2
Type (Add-on Acquisition) 8 of 11
State (Ohio) 1 of 2
Country (United States) 9 of 13
Year (2014) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-09-02 Fleet Complete

Toronto, Ontario, Canada

Fleet Complete is a provider of fleet, asset and mobile workforce management solutions and offers its software as a service to approximately 5,000 customers globally. Fleet Complete is based in Toronto, Ontario.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-04-01 BioRx

Cincinnati, Ohio, United States

BioRx LLC is a specialized pharmacy and infusion services provider that provides treatments for patients with ultra-orphan and rare, chronic diseases.

Sell $210M